Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Greenspan

Showing results (1-10 of 31) with videos related to

Pageof 4
Sort By:
Journal of the American Academy of Dermatology|April 2, 2019
Comment on "Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics"Andrew Greenspan, Sharon Popik
The New England Journal of Medicine|January 7, 2004
Early Alzheimer's diseaseRamy Mahmoud, Andrew Greenspan
Psychopharmacology|March 3, 2007
Efficacy and safety of risperidone in the treatment of elderly patients suffering from organic brain disease (organic brain syndrome): results from a double-blind, randomized, placebo-controlled clinical trialDieter Naber, Andrew Greenspan, Andreas Schreiner
The Journal of Clinical Psychiatry|November 2, 2005
Thyroid dysfunction during treatment with atypical antipsychoticsAndrew Greenspan, Georges Gharabawi, Joseph Kwentus
Drugs|May 23, 2018
Comment on: "Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes"Antonio Pires, Kavitha Goyal, Andrew Greenspan
Clinical Therapeutics|October 13, 2004
In vitro effects of risperidone and 9-hydroxy-risperidone on human platelet function, plasma coagulation, and fibrinolysisFred De Clerck, Yves Somers, Erik Mannaert, et al.
International Psychogeriatrics|August 2, 2006
Treating behavioral and psychological symptoms in patients with psychosis of Alzheimer's disease using risperidoneJonathan Rabinowitz, Ira Katz, Peter Paul De Deyn, et al.
Clinical Therapeutics|March 2, 2006
Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label studyJonathan M Meyer, Gahan Pandina, Cynthia A Bossie, et al.
Journal of Clinical Pharmacology|May 14, 2011
Effect of mild and moderate hepatic impairment on the pharmacokinetics and safety of carisbamateKenneth Moore, Peter Zannikos, Bhavna Solanki, et al.
International Journal of Geriatric Psychiatry|May 2, 2007
The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trialsIra Katz, Peter-Paul de Deyn, Jacobo Mintzer, et al.
Pageof 4

Showing results (1-10 of 31) with videos related to

Sort By:
Pageof 4
Journal of the American Academy of Dermatology|April 2, 2019
Comment on "Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics"Andrew Greenspan, Sharon Popik
The New England Journal of Medicine|January 7, 2004
Early Alzheimer's diseaseRamy Mahmoud, Andrew Greenspan
Psychopharmacology|March 3, 2007
Efficacy and safety of risperidone in the treatment of elderly patients suffering from organic brain disease (organic brain syndrome): results from a double-blind, randomized, placebo-controlled clinical trialDieter Naber, Andrew Greenspan, Andreas Schreiner
The Journal of Clinical Psychiatry|November 2, 2005
Thyroid dysfunction during treatment with atypical antipsychoticsAndrew Greenspan, Georges Gharabawi, Joseph Kwentus
Drugs|May 23, 2018
Comment on: "Switching Reference Medicines to Biosimilars: A Systematic Literature Review of Clinical Outcomes"Antonio Pires, Kavitha Goyal, Andrew Greenspan
Clinical Therapeutics|October 13, 2004
In vitro effects of risperidone and 9-hydroxy-risperidone on human platelet function, plasma coagulation, and fibrinolysisFred De Clerck, Yves Somers, Erik Mannaert, et al.
International Psychogeriatrics|August 2, 2006
Treating behavioral and psychological symptoms in patients with psychosis of Alzheimer's disease using risperidoneJonathan Rabinowitz, Ira Katz, Peter Paul De Deyn, et al.
Clinical Therapeutics|March 2, 2006
Effects of switching from olanzapine to risperidone on the prevalence of the metabolic syndrome in overweight or obese patients with schizophrenia or schizoaffective disorder: analysis of a multicenter, rater-blinded, open-label studyJonathan M Meyer, Gahan Pandina, Cynthia A Bossie, et al.
Journal of Clinical Pharmacology|May 14, 2011
Effect of mild and moderate hepatic impairment on the pharmacokinetics and safety of carisbamateKenneth Moore, Peter Zannikos, Bhavna Solanki, et al.
International Journal of Geriatric Psychiatry|May 2, 2007
The efficacy and safety of risperidone in the treatment of psychosis of Alzheimer's disease and mixed dementia: a meta-analysis of 4 placebo-controlled clinical trialsIra Katz, Peter-Paul de Deyn, Jacobo Mintzer, et al.
Pageof 4